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7*0 F”:- Jy = 6.5 Hz, J y d  = 3.5 Hz, 2’-H3,2.47 (ddd, 1, J*1, = 7.0 Hz, 2’-Hb), 2.95 (br 8, 1,5’-OH, DzO-exchangeable 5 OH 
3.72 (dd, 1, J3tA, = 3.5 Hz, J4,$, = 3.0 Hz, 4’-H), 4.04 (m, 1,5’-H), 
4.35 (dt, 1,3’-H), 5.94 (dd, 1, 1’-H), 7.25 (d, 1, &H), 9.10 (br 8, 1, 
3-H); ’% NMR (100 MHz, CDcg) 6 12.453,19.098,36.971,59.314, 
67.152, 86.953, 88.123, 111.350, 137.057, 150.363, 163.693. IR 
(CH2ClZ) 2115 (N3) cm-’. Anal. (C11H1$J604) C, H, N. 
FC EA; yield 80%; colorless crystale, mp 110-111 OC (EA-PE); 
1 - ( 3 ’ - A z i d o - ~ ~ , 6 ’ - t r i d e o l y - a - c t a l o f u  (6): 
Rf 0.51 (EA); ‘H NMR (400 MHz, CDclJ b 1.34 (d, 3, J (CH3, 
5’) = 6.2 Hz, CHJ, 1.92 (d, 3, J (bCH3,6) = 1.0 Hz, &CHJ, 2.36 
(ddd, 1, Jy* = 14.0 Hz, Jyblt 5.0 Hz, 2’-H,), 
2.54 (ddd, 1, Jn,l* = 7.0 Hz, Jn,y = 7.0 Hz, 2’-H&, 3.75 (dd, 1, 
J3,,4, 5.0 Hz, J 4 t 8  = 3.0 Hz, 4’-H), 3.99 (dq, 1, 5’-H), 4.34 (dt, 
NMR (100 MHz, CDCl3 6 12.513,20.256,36.901,61.121,67.476, 
86.538, 87.366, 111.268, 136.854, 150.250, 163.640; IR (CH&) 
7.0 Hz, Jy,,y 
1,3’-H), 6.07 (t, 1, l’-H), 7.43 (d, 1, 6-H), 9.00 (br 8,1,3-H); 13C 
2115 (N3) cm-’. Anal. (C11H1&04) C, H, N. 
Anti-HIV Assays. The HIV cytopathicity away in human 
T-lymphocyte MT-4 cells haa been described previously?2*” 
Briefly, MT-4 cells, subcultured 1 day before the start of the 
experiment, were adjusted to 5 X 105 ceh/mL and infected with 
HIV (HTLV-111~) at 400 CCIDw/mL. Then, 100 pL of the in- 
fected cell suspension was transferred to w e b  of a microtiter tray 
containing 100 pL of varying dilutions of the test compounds. 
After 5 days of incubation at  37 OC, the number of viable cells 
1992,35, 3023-3027 3023 
(33) 
Balzarini, J.; Pauwels, R.; Baba, M.; Robins, M. J.; Zou, R.; 
Herdewijn, P.; De Clercq, E. The 2’,3’-Dideoxyribose of 2,6- 
Diaminopurine Selectively Inhibita Human Immunodeficiency 
V i  (HIV) Replication in vitro. Biochem. Biophys. Res. 
Commun. 1987,145,269-276. 
Balzarini, J.; Naesens, L.; Herdewijn, P.; Roeenberg, I.; Holy, 
A.; Pauwels, R.; Baba, M.; Johns, D. G.; De Clercq, E. Marked 
in vivo Antiretrovirus Activity of 9-(2-Phosphonylmethoxy- 
ethyl)adenine, a Selective Anti-Human Immuno deficiency 
Virus Agent. Roc.  Natl. Acad. Sci. U.S.A. 1989, 332-336. 
was recorded microecopically in a hematocytometer following the 
trypan blue exclusion procedure. 
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152nd Street, Miami, Florida 33177. Received March 16, 1992 
Dispiro-l,2,4,5tetraoxanes 2-4 were synthesized as potential peroxide a n t h a l a d  * drugs. Theyhadcurativeactivity 
against Plasmodium berghei in vivo at single doses of 320 and 640 mg/kg which c o n f i i s  earlier unpublished da ta  
Moreover, artemisinin (1) and 4 had equivalent ED”s against P. berghei in vivo in the multiple-dose Thompson 
tat; neither showed any evidence of acute toxicity at total doses of more than 12 g/kg. Dispiro-l,2,4,5-tetraoxane 
4 had ICm’s comparable to those of 1 against Plasmodium falciparum clones in vitro. These results confirm the 
potential of dispiro-l,2,4,5-tetraoxanes as a new claes of inexpensive peroxide antimalarial drugs. 
As a result of an apparent association between the 
peroxide functional group and antimalarial activity,2 a 
substantial effort has been devoted to developing new 
peroxide anti“& . Our early attemptaa4 in this regard 
led us to conclude that an endoperoxide ketal is a mini- 
mum but insufficient structural requirement for an ef- 
t University of Nebraska Medical Center. 
*Walter Reed Army Institute of Research. 
5 University of Miami. 
11 University of Nebraska at  Omaha. 
fective peroxide-containing antimalarial. Most work, 
however, has centered around artemisinin (l) ,  the proto- 
(1) Presented in part at the 40th Annual Meeting of the American 
Society of Tropical Medicine and Hygiene, Boeton, MA, 1991. 
(2) Vennemtrom, J. L.; Eaton, J. W. Oxidants, Oxidant Drugs and 
Malaria. J. Med. Chem. 1988,31,1269-1277, and references 
cited therein. 
(3) Vennerstrom, J. L.; Acton, N.; Lin, A. J.; Klayman, D. L. 
Peroxidea as Oxidant Antimalarials. Drug Des. Delivery 1989, 
4,4564.  
OO22-2623/92/ 1835-3023$03.00/0 (0 1992 American Chemical Society 
3024 Journal of Medicinal Chemistry, 1992, Vol. 35, No. 16 Vennerstrom et al. 
Table I. Antimalarial Activity of Dis~iro-1,2,4.5-tetraosanes 2-4 Compared to Artemisinin (1) 
P. falciparum P. berghei 
ICE4 (nM) T - Ca (days) at the following doses (mg/kg)' 
compd D-6 W-2 resistance indexb 20 40 80 160 320 640 
1 4.7 2.2 0.47 1.5 1.7 2.3 3.9 5.1 C-2d 
2 50 13 0.26 1.5 1.3 2.4 5.5 c-1 NA 
0.6 1.0 3.8 5.8 7.4A c-2e 
3 8.2 58 7.1 0.1 0.4 0.1 2.4 1.9 c- 1 
0.3 0.5 2.0 3.2 13.OA c-1' 
4 6.9 3.4 0.49 0.2 1.8 1.6 9.6A c-1 c-3 
0.7 1.2 5.0 12.OA c-3 c-5' 
" T  - C is the mean survival time of the treated mice beyond that of the control animals. This value must be 2 twice the mean suirival 
time (6.2 days) of the control animals to be considered active (A). Survival beyond 60 days is considered curative (C), and deaths from 0-2 
days poetinfection are attributed to toxicity (T). *ICw (W-2)/ICE4(D-6) ratio. eSingle dose administered 8c 3 days poetinfection, n = 5. dT 
- C values for 1 represent averages of eight data sets from WRAIR. e Unpublished data.'* 
type peroxide antimalarial, in an effort to discern ita 
structureactivity relationship (SAR).6 These investiga- 
tions identify the 1,2,4trioxane heterocycle as the critical 
(4) We found that two tricyclic peroxy ketals (7-acetyl-1,4,6-tri- 
metbyl-2,3,5,10-tetraoxatricy~lo[4.3.l.0'~~]decane d 1,4,6- 
trimethyl-2,3,5,7,8~ntaoxatri~~o[4.2.2.0'~d~e described 
by Biachoff, C.; Rieche, A. b r  die Bildung cyclischer Per- 
oxide a w  Mehrfachketonen. Liebigs Ann. Chem. 1969, 725, 
87-92, have ICE4's >300 nM against P. falcipamm in vitro and 
are inactive against P. berghei with toxicity observed at a 640 
mg/kg doee. We thank Prof. Christophe Morin, of the Univ- 
ersite de Grenoble, St.-Martin DHeres, France for bringing 
these peroxides to our attention ae potential antimalarials. 
(5) (a) Acton, N.; Klayman, D. L. Conversion of Artemisinin 
(Qinghaoeu) to Iso-Artemisitene and to 9-Epi-Artembinin. 
Phnta Med. 1987,266-268. (b) Imakura, Y.; Yokoi, T.; Yam- 
agishi, T.; Koyama, J.; Hu, H.; McPhail, D. R; McPhail, A. T.; 
Lee, K.-H. Synthesis of Deaethauoqinghaoeu, a Novel Ana- 
logue of the Antimalarial Qinghaosu. J. Chem. SOC. Chem. 
Comm. 1988,372-374. (c) Avery, M. A.; Jennings-White, C.; 
Chong, W. K. M. Synthesis of a C,D-Ring Fragment of Artem- 
binin. J. Org. Chem. 1989,54,1789-1792. (d) Avery, M. A.; 
Jennings-White, C.; Chong, W. K. M. Simplified analogues of 
the Antimalarial Artemisinin: Synthesis of 6,g-Desmethyl- 
artemismin. J. Org. C k m .  1989,54,1792-1795. (e) Lin, A. J.; 
Lee, M.; Klayman, D. L. Antimalarial Activity of New 
Water-Soluble Dihydroartemisinii Derivatives. 2. Stereo- 
specificity of the Ether Side Chain. J.  Med. Chem. 1989,32, 
1249-1252. (f) Jefford, C. W.; Velarde, J.; Bemardinelli, G. 
Synthesis of Tricyclic Arteannuin-Like Compounds. Tetra- 
hedron Lett. 1989,30,4485-4488. (g) Avery, M. A.; Chong, W. 
K. M.; Bupp, J. E. Tricyclic Analogues of Artemisinin: Syn- 
(-)-5-Nor-4,5-secoartemisinin. J.  Chem. SOC. Chem. Comm. 
1990,1487-1489. (h) Jung, M.; Li, X.; Bustce, D. A,; ElSohly, 
H. N.; McChesney, J. D.; Milhow, W. K. Synthesis and An- 
timalarial Activity of (+)-Deoxoartemisinin. J. Med. Chem. 
1990,33,1516-1518. (i) Imakura, Y.; Hachiya, K.; Ikemoto, T.; 
Shinauke, Y.; Kihara, M.; Kobayaehi, S.; Shngu, T.; Milhow, 
W. K.; Lee, K.-H. Acid Degradation Products of Qinghaosu 
and their Structure-Activity Relationships. Heterocycles 1990, 
31,1011-1016. (j) Avery, M. A.; Chong, W. K. M.; Detre, G. 
Synthesis of (+)-8a,S-Secoartemisinin and Related Analogs. 
Tetrahedron Lett. 1990, 31, 17-1802. (k) Zaman, S. S.; 
Sharma, R. P. Some Aspects of the Chemistry and Biological 
Activity of Artemisinin and Related Antimalarials. Hetero- 
cycles 1991, 32, 1593-1638. (1) Riicker, G.; Walter, R. D.; 
Manna, D.; Mayer, R. Antimalarial Activity of Some Natural 
Peroxides. Phnta Med. 1991,57,295-296. (m) Lin, A. J.; Li, 
L.-Q.; Milhow, W. K.; Klayman, D. L. Antimalarial Activity 
of Dihydroartemisinin Derivatives. 4. Stereoselectivity of 
9-Hydroxy Esters. Med. C k m .  Res. 1991,1,20-23. (n) Pos- 
ner, G. H.; Oh, C. H.; Milhow, W. K. Olefin Oxidative Cleav- 
age and Dioxetane Formation Using Triethylsilyl Hydrotri- 
oxide: Applications to Preparation of Potent Antimalarial 
1,2,4-Tetraoxanes. Tetrahedron Lett. 1991,34,4235-4238. (0) 
Posner, G. H.; Oh, C. H.; Gerena, L.; Milhow, W. K. Ex- 
traordinarily Potent Antimalarial Compounds: New, Struc- 
turally Simple, W i l y  Synthesized, Tricyclic 1,2,4-Trioxanes. 
J. Med. Chem. 1992,35, 2459-2467. 
thesis and Antimalanal * Activity Of (+)-4,5-S~0&d~h and 
Total Dose ( m a g )  
Figure 1. Dosereaponse c w e a  for 1 (hatched line) and 4 (wlid 
line) in the Thompson test. Doses of 1 and 4 were administered 
sc twice daily for 3 days, starting at day 3 postinfection. 
pharmacophore, and suggest that an intact ABC ring 
system is required for maximum potency. 
0 
1 
Others- have synthesized structurally diverse 1,2,4- 
trioxanes which show mixed results when screened for 
(6) Kepler, J. A.; Philip, A.; Lee, Y. W.; Morey, M. C.; Carroll, F. 
I. 1,2,4-Trioxanes ae Potential Antimalarial Agents. J. Med. 
Chem. 1988,31,713-716. 
(7) Singh, C. Preparation of @-Hydroperoxides by Photo- 
oxygenation of Allylic Alcohols and their Elaboration into 
1,2,4-Triosanes. Tetrahedron Lett. 1990,31,6901-6902. 
(8)  Jefford, C. W.; McCoran, E. C.; Boukouvalaa, J.; Richardeon, 
G.; Robinson, B. L.; Peters, W. Synthesis of New 1,2,4Triox- 
anea and their Antimalarial Activity. Helu. Chim. Acta 1988, 
71, 1805-1812. 
(9) Jefford, C. W.; Kohmoto, 5.; Roseier, J. C.; Peters, W.; Mil- 
how, W. K. Synthetic 1,2,4-Triosanes, A New Class of Anti- 
malarials. 40th Annual Meeting of the American Society of 
Tropical Medicine and Hygiene, Boston, MA, 1991, Abstract 
363. 
New Antimalarial Peroxides 
antimalarial activity. For example, Kepler et al.s syn- 
thesized 10 1,2,4-trioxanes that were inactive against P. 
berghei in vivo; the most active compounds in this series 
had ICm's between 24 and 100 ng/mL against P. falcipa- 
rum in vitro. Singh7 synthesized several 1,2,4trioxanes 
with ICm's ranging from 3 to 222 ng/mL against P. fal- 
ciparum in vitro. Jefford et al? reported that 10 1,2,4- 
trioxanes were either inactive or much lese active than was 
1 against P. berghei in mice. More recently, however, 
Jefford et aL9 described excellent in vitro and in vivo an- 
timalarial activity for numerous 1,2,44rioxanes, many of 
which were more potent than 1. 
It must be noted that 1 is curative against P. berghei 
only at 640 mg/kg in the single-dose Rane screenlo (Table 
I); ita curative activity improves dramatically, however, 
when a multiple-dose protocol is followed." In this light, 
unpublished datal2 that indicates several dispiro-1,2,4,5- 
tetraoxanes13 are curative at single doses of 320 and 640 
mg/kg is remarkable. We now confirm this curative in vivo 
activity and show that di8piro-l,2,4,5-tetraoxanes are also 
active against P. falciparum in vitro. 
Chemistry 
From this unpublished data,12 we chose three of the 
more active dispiro-l,2,4,5-tetraoxanes (2-4) which were 
obtained via acid-catalyzed peroxyketalization between a 
1:l mole ratio of the substituted cyclohexanone and hy- 
drogen peroxide. A modified procedure of Braunworth and 
Crosby14 using 30% H202 and H 8 0 4  in aqueous EtOH at 
0 OC afforded 212 and 3.16J6 We found the procedure of 
Journal of Medicinal Chemistry, 1992, Vol. 35, No. 16 3025 
acetic acid at room temperature to be the k t  method for 
the synthesis of 4.1611s 'H and 13C "MI2 spectroscopy 
indicate that 2 and 3 are each mixtures of meso and d,l 
stereoisomers, whereas 4 is a single stereoisomer. For 
example, 4 has a seven-line '3c NMR spectrum consistent 
with the presence of a single stereoisomer, whereas 2 and 
3 each have 2-3-fold the number of lines expected for that 
of a single diastereomer. Furthermore, 'H NMR spectra 
show a single doublet for the methyl groups in 4, and 
cloeely overlapping doublets for the methyl groups in 2 and 
3. Previous X-ray crystallographic structural analysis of 
417 has shown that it exista as a single meso stereoisomer. 
Antimalarial Activity 
In vivo antimalarial activity for 2-4 against a drug- 
sensitive strain (KBG 173) of P. berghei in the single-dose 
Rane screenlo was comparable (Table I) to unpublished 
datal2 with cures seen at doses of 320 and 640 mg/kg. A 
multiple-dose Thompson tesP  against P. berghei (Figure 
1) revealed no significant difference between ED,'s of 1 
(607 mg/kg) and 4 (382 mg/kg) at the 95% confidence 
intervals using nonlinear regres~ion.'~ Both druga dem- 
onstrated a remarkable lack of acute toxicity; no death 
were observed at total doses of more than 12 g/kg. 
In vivo antimalarial activity against the D-6 and W-2 
clones of P. falciparum (Table I) using a semiautomated 
microdilution techniquem3l indicates that 2 and 3 are 2- 
to 26-fold lees potent than is 1; curiously, 3, in contrast to 
1,2, and 4, has a high resistance index. Dispiro-1,2,4,5- 
tetraoxane 4 is only 1.5-fold less potent than is 1 against 
both P. falciparum clones. The excellent potency of 4 
against P. falciparum in vitro is consistent with ita superior 
single-dose in vivo activity in comparison to 2 and 3. The 
range of in vitro potencies for 2-4 is also consistent with 
unpublished data of Doorenbos and Decker'% who noted 
considerable changes in in vivo antimalarial activity with 
relatively small structural modifications. 
Discussion 
Even though an overlay of energy-minimized structures 
of 1 and 4= using PCMODEL reveals substantial structural 
2 3 
4 
Sanderson et al.16 using 30% Hz02, HCl, and HCIOl in 
Ager, A. L., Jr. Rodent Malaria Models. In Handbook of Ex- 
perimental Parasitology: Antimalarial Drugs I .  6811; Peters, 
W., Richards, W. H. G., Eds.; Springer-Verlag: Berlin, 19&1; 
pp 226-227. 
Lin, A. J.; Klayman, D. L.; Milhous, W. K. Antimalarial Ac- 
tivity of New Water-Soluble Dihydroartemisinin Derivatives. 
J. Med. Chem. 1987,30,2147-2150. 
(a) Doorenbos, H. E.; Decker, D. L. Antimalarial Synthesis. 
Annul Technical Report No. AM-1 A-73, The Dow Chemical 
Company, 1973. (b) Data from Walter Reed Army Institute 
of Research (WRAIR). 
Antimalarial data (P. berghei) from WRAIR indicates that 
several 1,2,4,btetraoxanes derived from cyclic ketones are cu- 
rative, whereas thoee derived from acyclic ketones and aldeh- 
ydes are not. Cyclic tripemxides (1,2,4,5,7,&hexaoxonanes) 
which are kinetic producta (Story, P. R; Lee, B.; Bishop, C. E.; 
Denson, D. D.; Busch, P. Macrocyclic Synthesis. 11. Cyclo- 
hexanone Peroxides. J. Org. Chem. 1970,35,3059-3062) of 
acid-catalyzed peroxyketalization between hydrogen peroxide 
and ketones are without activity. 
Braunworth, J. B.; Crosby, G. W. Process for Preparing Di- 
cycloalkylidene Diperoxides. U.S. Patent 3,116,300, 1963, 
1162. 
Sanderson, J. R.; Paul, K.; Story, P. R.; Denson, D. D.; Alford, 
J. A. Macmcyclea. The Synthesis and Thermal Decomposition 
of Some Disubstituted Dicyclohexylidene Diperoxides. Syn- 
thesis 1975, 159-161. 
Dilthey, W.; Inckel, M.; Stephan, H. Die Oxydation der Ketone 
mit Perhydrol. J.  Prakt. Chem. 1940,164, 219-237. 
(a) Bladon, P.; McCullough, K. J.; Morgan, A. R.; Nonhebel, 
D. C.; P a w n ,  P. L.; White, G. J. Ketone-derived Peroxides. 
Part IV. Structural Studies of cyclic Di- and Tri-peroxides 
Derived from Ketones. J.  Chem. Res. Synop. 1980,284-285. 
(b) Bladon, P.; McCullough, K. J.; Morgan, A. R.; Nonhebel, 
D. C.; Pauson, P. L.; White, G. J. Ketone-derived Peroxides. 
Part IV. Structural Studies of cyclic Di- and Tri-peroxides 
Derived from Ketones. J. Chem. Res. Miniprint 1980, 
3701-3716. (Bond angles and distances, however, were not 
disclosed in the unpublished X-ray crystallographic analysis 
of 4 noted in ref 17(b). 
Ager, A. L., Jr. Rodent Malaria Models. In Handbook of Ex- 
perimental Parasitology: Antimalarial Drugs I .  6811; Peters, 
W., Richards, W. H. G., Eds.; Springer-Verlag: Berlin, 1984, 
The % cure versus doee data from the Thompson test were fit 
to a Hill Equation using nonlinear regression (PCNONLIN SCI, 
Lexington, KY). Hill Equation: R = R-O'/EDm + OH 
where R ,  is the maximum effect (100% cure), EDm is the 
dose at which 50% cure occurs, H is the Hill coefficient or 
slope factor, and D is the dose. 
Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. 
Quantitative assessment of antimalarial activity in vitro by a 
semiautomated microdilution technique. Antimicrob. Agents 
Chemother. 1979,16, 710-718. 
Milhous, W. K.; Weatherly, N. F.; Bowdre, J. H.; Desjardins, 
R. E. In vitro activities of and mechanisms of resistance to 
antifolate antimahial drugs. Antimicrob. Agents Chemother. 
1985,27, 525-530. 
pp 231-232. 
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dissimilarity between the two as exemplified by the boat 
1,2,4-trioxane in 1 and the chair 1,2,4,5-tetraoxane in 4, 
structural correlations between artemisinin and 4 are of 
interest. For example, VT 13C NMR e~periments'"~ in- 
Vennerstrom et al. 
dicate that 4, like 1, exists as a relatively rigid structure. 
If one speculates that the 1,2,4-trioxane in 1 corresponds 
with the 1,2,4,5-tetraoxane in 4, several correlations are 
evident: (1) the oxygen-substituted carbon atom (C-12) 
in 1 is replaced with an oxygen atom in 4; (2) the C-3 
methyl and 4,bethano bridge (which forms the A-ring in 
1) are replaced with a methyl-substituted spirocyclohexane 
in 4; and (3) the C-ring, a substituted spirocyclohexane 
with respect to the 1,2,4-trioxane (B-ring) in 1 may cor- 
respond to the other spirocyclohexane ring in 4. These 
correlations are consistent with the observation that full 
potency is seen with certain ABC ring analogs of l.5i*60 
As the peroxide bond is absolutely essential for anti- 
malarial activity in 1,% it is likely that at least one of the 
peroxide bonds in 4 is required. To partially address this 
question, work is in progress to screen the analogous dis- 
piro-1,2,4-trio~olanes~~ and dispiro-1,2,4-trioxanes which 
differ from dispiro-1,2,4,5-tetraoxanes by removal of one 
oxygen atom or by replacement of an oxygen atom by a 
methylene carbon, respectively. 
In summary, we suggest that the potency observed with 
Models of 1 and tram-3,6-dimethoxy-1,2,4,5-tetraoxane were 
constructed and minimized ushg PCMODEL. Since a compari- 
son of bond angles (*0.70°, *1.57"), and bond length (kO.019 
A, k0.013 A) of 1 and the modeled tetraoxane, respectively, 
with published X-ray data (Leban, I.; GoliE, L.; Japelj, M. 
Crystal and Molecular Structure of Qinghaosu: a Redetermi- 
nation. Acta Pharm. Jugosl. 1988,38,71-77. Chiang, C.-Y.; 
Butler, W.; Kuczkowski, R. L. The Synthesis, X-Ray Struc- 
tural Analysis, and Anomeric Effect in tram-3,6-Dimethoxy- 
1,2,4,5-tetroxane. J. Chem. SOC. Chem. Comm. 1988,465-466) 
was excellent, models of the two d,l and two meso stereoiso- 
mera of 4 were ale0 constructed and minimized. Meeo isomer 
4, or 1(S),10(R)-dimethyl-7,8,15,16-tetraox~ispiro[5.2.5.2]- 
hexadecane was found to be the more stable stereoisomer. 
This result is consistent with unpublished X-ray crystallo- 
graphic data noted in ref 17(b). 
(a) Khyman, D. L. Qinghaosu (Artemisinin): An Antimalarial 
Drug from China. Science (Washington, DC) 1985, 228, 
1049-1066. (b) Luo, X.-D.; Shen, C.-C. The Chemistry, 
Pharmacology, and Clinical Applications of Qinghaosu (Ar- 
t e m i s i i )  and ita Derivatives. Med. Res. Rev. 1987, 7,29-52. 
We have synthesized and screened several aza analogs of dis- 
piro-1,2,4trioxolanes, namely 1,2-dioxa-4-azacyclopentane~ 
with spirocyclohexane rings at the 3 and 5 positions (Hawkins, 
E. G. E. Reactions of Organic Peroxides. Part X. Amino- 
peroxides from Cyclohexanone. J. Chem. SOC. C 1963, 
2663-2670), and found them to be without antimalarial activ- 
ity. 
4 against P. fakiparum in vitro confirms the potential of 
dispirel,2,4,5-tetraoxanes as a new class of peroxide an- 
timalarial drugs. An expected advantage of these com- 
pounds with respect to 1 and ita semisynthetic derivatives 
is a one-step synthesis using inexpensive starting materiala 
VB a multistep synthesis or isolation from Artemisia ~IUUM. 
Work is in progress to synthesize additional dispiro- 
1,2,4,5-tetraoxanes to def ie  SAR and optimize antima- 
larial activity. 
Experimental Section 
Molecular modeling experiments were performed with PCMODEL 
4.0 (Serena Software). Melting points were taken with a Mel- 
Temp capillary apparatus. IR spectra were run as KBr disca on 
a Perkin Elmer 1420 spectrophotometer. NMR spectra were 
obtained with Varian XL-300 or Bruker AC-200 spectrometers 
using deuteriatad chloroform and TMS as an internal standard. 
M i c r d y a e a  were performed by M-H-W Laboretoria, Phoenix, 
AZ. Analytical HPLC of 2-4 was performed on a 5-pm silica 
column (Alltech Spherisorb 250 X 4.6 mm) using a 973 heptane 
tert-butyl methyl ether mobile phase with detection at 220 nm. 
All reagents are commercially available from Aldrich Chemical 
Co. with the exception of 3,bdimethylcycloheuone. The latter 
was prepared by Jones oxidation of 3,5-dimethylcyclohexol. 
Synthesis. 2,4,11,13-Tetramethy1-7,8,15,16-tetraoxo- 
dia~iro[62.62]hezaaecanexadwane (2). Thirty percent H& (23.8 "01, 
0.810 g) and 3,5dimethylcyclohexe (23.8 mmol,3.00 g) were 
added by consecutive dropwise addition to a stirred solution of 
water (26 mL), EtOH (27 mL), and HzSO4 (50 mL) at 0 "C. 
Stirring was continued for 14 h at  0 OC. The resulting white 
precipitate was filtered, washed with watm, and air-dried to afford 
2 (2.64 g, 78%): mp 172-173 "C (CH3CN) (lit.lZ mp 172-173 "C); 
IR 2980,2920,2900,2840,1445 cm-'; 'H NMR 6 0.45-0.75 (m, 
2 H), 0.77-1.22 (m, 16 H), 1.4S1.93 (m, 8 H), 2.05-2.34 (m, 2 H); 
13C NMR S 21.87, 21.94,22.02, 28.29,28.63, 28.93, 36.40, 36.50, 
40.12, 43.23, 43.38, 108.68, 109.05. hd .  (C&&4) c, H. 
3 , l ~ D i m e t h y l - 7 ~ , 1 5 , l ~ ~ t ~ 0 ~ ~ ~ ~ [ 5 2 . 6 2 ] h e z a a e c a n e ~ d ~ ~  
(3): 0.78 g, 70%; mp 71-72 "C (64 MeOH/HzO) (lit.12*16,16 mp 
71-72 "C); IR 2950,2930,2860,1445 cm-'; IH NMR S 0.75-1.02 
(m, 6 H), 1.03-1.80 (m, 14 H), 2.01-2.41 (m, 4 H); NMR 6 21.51, 
21.60,21.63,28.50,28.57,30.78,30.93,30.96,31.06,31.11,31.16, 
C, H. 
l(S),1(R)-D~ethyl-7,8,15,16-tetraoxodlspiro[52~2]hezaaecanex- 
adecane (4). Thirty percent HzOz (0.1 mol, 3.40 g) was added 
by slow dropwise addition to a stirred mixture of 2-methyl- 
cyclohexanone (0.1 mol, 11.22 g) and 2 N HC1 (1 mL) at room 
temperature. Stirring was continued for 12 h a t  mom temperature 
at which time glacial AcOH (75 mL) and 10% HC104 (4 mL) were 
added. Stirring was continued for an additional 12 h a t  room 
temperature. Water (150 mL) was added, and 4 (7.70 g, 60%) 
was collected as a white solid after filtration and washing with 
water. mp 105-106 "C (MeOH) (lit.'6J6 mp 105-106 "C); IR 2940, 
2860, 1460, 1440 cm-I; 'H NMR 6 1.01 (d, J = 6.9 Hz, 6 H), 
1.19-1.98 (m, 16 H), 2.73-3.05 (m, 2 H); NMR S 13.65,22.46, 
24.54, 29.41, 30.71, 38.21, 109.17. Anal. (CI!H,O4) C, H. 
Screening Methods. In vitro activity a g w t  P. fakiparum 
was determined using a modification of the semiautomated mi- 
crodilution technique of Desjardins et aL20 and Milhoue et aLZ1 
Two P. falciparum malaria parasite clones, designated as Sierra 
Leone (D-6) and Indochina (W-2), were used in susceptibility 
testing. The former was resistant to mefloquine, and the latter 
to chloroquine (CQ), pyrimethamine, sulfadoxine, and quinine. 
Test compounds were dissolved in dimethyl sulfoxide and solu- 
tions serially diluted with culture media. Erythrocytes with 
0.25-0.5% parasitemia were added to each well of a 96-well 
microdilution plate to give a final hematocrit of 1.5%. Inhibition 
of uptake of tritiated hypoxanthine was used as an index of 
antimalarial activity. Results were reported as ICso (ng/mL) 
values. 
In vivo activity against P. berghei was obtained against a 
drug-sensitive strain of P. berghei (strain KBG 173).1° Each test 
compound was administered to five male mice per dilution in a 
single ~ u b c u t a n ~ ~  (sc) doee 3 days after infection. Results were 
expressed in T - C values which indicate the mean survival time 
31.65,31.73,31.76,31.83,107.51,107.58,107.71. Anal. (c&&4) 
J. Med. Chem. 1992,35,3027-3033 3027 
of the treated mice beyond that of the control animals; untreated 
mice survive on average 6.2 days. Compounds were classified as 
active (A) when the mean survival time of the treated mice is twice 
that of the controls (>12.4 days), and curative (C) when one or 
more test animals live 60 days postinfection. Deaths from 0-2 
days post-treatment were attributed to toxicity (TI. 
A alight modification ofthe T h o m p n  teatlswas used to further 
quantify antimalarial activity and toxicity. Five week old CD-1 
mice were inoculated on day 0 with 5 X lOe trophozoites of P. 
berghei (strain KBG 173) obtained from an infected m o u e  at 
60% parasitemia, diluted with uninfected m o u e  blood, and in- 
jected intraperitonealy. On days 3-5, each group of seven mice 
were h t e d  sc with the compound ta be teeted in eight total doees, 
twice a day for 3 days. A range of doses sufficient to generate 
a doseresponse curve was wed. Blood fiis were taken 1 day 
after completion of drug treatment (day 6) and weekly thereafter 
until day 60. Parasitemia values were determined from Giem- 
sa-stained blood films Drug activity was evaluated by suppreesion 
of parasitemia, extension of survival time, and curative activity. 
Mice living 60 days postinfection and blood film negative were 
considered cured. A drug was considered to be toxic if the mice 
died before the untreated control mice. An advantage of this 
method of evaluation is the ability to assess efficacy and acute 
toxicity at the same time in the same model. 
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Thieno[2,3-b ]furan-2-sulfonamides as Topical Carbonic Anhydrase Inhibitors 
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Novel 5[ (alkylamino)methyl]thieno[2,3-b]furan-2-sulfonamides were prepared and evaluated in vitro for inhibition 
of human carbonic anhydrase I1 (CA 11) and ex vivo for their ability to inhibit CA 11 in the albino rabbit eye after 
topical administration. Compound lla was found to lower intraocular pressure (IOP) in both the a-CT ocular 
hypertensive albino rabbit and the normal albino rabbit, but was ineffective at lowering IOP in a hypertensive, 
pigmented monkey model. Sice lla was highly bound to ocular pigment, a aeries of less basic analogs was prepared. 
Examples in this series were both less extensively bound to ocular pigment and more active at reducing IOP in 
pigmented rabbits after topical dosing. Key examples displayed moderate reactivity toward glutathione. 
Introduction and 5- [ (hydroxyalkyl)sulfonyll thiophene,' have been re- 
wish to report on the biological eduation of a series of 
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